seekingalpha.com
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Ovid Therapeutics Inc.OVIDNASDAQ
Loading
Latest News
Loading news...
fool.com
Here's Why Ovid Therapeutics Stock Popped Higher Today
OV329 may be safer and more potent than existing treatments. A $60M private placement will fund further development.
benzinga.com
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.
zacks.com
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.13 per share a year ago.
globenewswire.com
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today provided pipeline progress and business updates, including financial results for the fourth quarter and full year ended December 31, 2025. The Company reported favorable topline safety, tolerability and pharmacokinetics (PK) findings from the 7 mg dose cohort of OV329, its next generation GABA-aminotransferase (GABA-AT) inhibitor. Additionally the Company announced it will add complementary development programs for OV329, expanding into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS) which is funded by a private placement financing expected to result in gross proceeds of $60.0 million, before deducting placement agent fees and offering expenses.
globenewswire.com
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to satisfaction of customary closing conditions.
globenewswire.com
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced that the Company's management will participate in three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference – Wednesday, February 25th at 11:20 am ET 46th Annual TD Cowen Health Care Conference – Wednesday, March 4th at 9:50 am ET Leerink Partners Global Healthcare Conference 2026 – Wednesday, March 11th at 3:00 pm ET A live webcast of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 days.
seekingalpha.com
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots
Ovid Therapeutics targets neuronal hyperexcitability with two small-molecule platforms. 1) OV329 (GABA-AT inhibition) and 2) KCC2 direct activators for neuropsychiatric disorders. OV329 Phase 2a in drug-resistant focal seizures is planned for Q2 2026. And we should get its topline data by mid-2027. OVID's KCC2 program leads with OV4071, which targets PD/LBD psychosis and schizophrenia. Its IND is expected by Q1 2026, and its Phase 1 by Q2 2026.
defenseworld.net
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have been given a consensus rating of "Buy" by the eleven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy
defenseworld.net
Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID
Assenagon Asset Management S.A. lifted its position in shares of Ovid Therapeutics (NASDAQ: OVID) by 112.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 924,576 shares of the company's stock after buying an additional 488,956 shares during the quarter. Assenagon Asset
globenewswire.com
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs) Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brain Pharmacokinetics for OV350 were as predicted, and will inform dosing strategies for future KCC2 development programs OV4071 (oral) is on track for regulatory submission for a Phase 1/1b clinical trial in Q1 2026 NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced results from its Phase 1 study of OV350, the first-ever KCC2 direct activator known to be dosed in humans. The study met its primary objectives to evaluate safety, tolerability and pharmacokinetics.
globenewswire.com
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance.
zacks.com
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
globenewswire.com
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong inhibitory activity and a potential best-in-category safety profile in a Phase 1 study, supporting advancement into planned Phase 2 patient studies OV329 Phase 1 results selected for late-breaking poster presentation at the 2025 American Epilepsy Society (AES) annual meeting Ovid's first-in-class KCC2 direct activator portfolio is progressing on-track with first-in-human data for OV350 intravenous (IV) expected in Q4 2025 and the first-ever oral KCC2 direct activator, OV4071, anticipated to enter the clinic in Q2 2026 Completed private placement of up to $175 million in gross proceeds, including initial closing of approximately $81 million, expected to extend anticipated cash runway into 2H 2028 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced a Chief Executive Officer (CEO) succession plan under which Meg Alexander will assume the role of CEO and join Ovid's Board of Directors, effective January 1, 2026.
zacks.com
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
zacks.com
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com
Ovid Therapeutics Inc. - Special Call
Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Ritu Baral - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C.
globenewswire.com
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants
globenewswire.com
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies.